Trials / Recruiting
RecruitingNCT06951503
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
A Randomized, Controlled, Multicenter Phase III Clinical Study of AK112 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy in First-line Metastatic Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 560 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112 | iv, q2w |
| DRUG | Oxaliplatin | iv, q2w |
| DRUG | Irinotecan | iv, q2w |
| DRUG | Leucovorin and 5-FU | iv, q2w |
| DRUG | Bevacizumab | iv, q2w |
Timeline
- Start date
- 2025-05-27
- Primary completion
- 2027-01-13
- Completion
- 2029-01-07
- First posted
- 2025-04-30
- Last updated
- 2026-03-04
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06951503. Inclusion in this directory is not an endorsement.